US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd., (SHE: 000963) regarding their joint development of the type 2 diabetes drug TTP273. Huadong, confirming the cancellation, stated that TTP273 was found to be inferior to its own drug candidate, HDM1002.
TTP273, a first-in-class, non-peptide, and highly selective GLP-1R agonist, was developed by vTv utilizing its TTP platform. In December 2017, following the completion of Phase IIa trials, Huadong entered into a $33 million licensing agreement with vTv for exclusive intellectual property and commercialization rights in 16 countries and regions, including Greater China, South Korea, and Australia.
HDM1002, Huadong’s proprietary oral GLP-1 receptor agonist, has shown significant activation of the GLP-1 receptor, leading to increased cAMP production and improvements in glucose tolerance, blood sugar levels, and weight loss, with a favorable safety profile in preclinical trials. The drug candidate is currently in Phase Ib clinical studies, with clinical trial applications filed in China in February and the United States in April of the previous year.- Flcube.com
